Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 2,368 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,368 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the completion of the transaction, the chief financial officer now directly owns 37,270 shares of the company’s stock, valued at $905,661. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Houte Hans Van also recently made the following trade(s):

• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.22, for a total value of $504,400.00.
• On Thursday, August 1st, Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock. The stock was sold at an average price of $21.45, for a total value of $74,581.65.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $1.13 during midday trading on Wednesday, reaching $24.07. 761,824 shares of the company’s stock were exchanged, compared to its average volume of 885,869. Nurix Therapeutics, Inc. has a 52-week low of $4.96 and a 52-week high of $27.60. The stock has a market capitalization of $1.71 billion, a PE ratio of -8.66 and a beta of 2.22. The business’s fifty day moving average price is $24.18 and its two-hundred day moving average price is $20.14.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of Nurix Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NRIX. Redmile Group LLC increased its holdings in Nurix Therapeutics by 37.7% in the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after buying an additional 1,226,497 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics in the second quarter valued at approximately $26,778,000. Candriam S.C.A. boosted its stake in Nurix Therapeutics by 30.5% in the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after acquiring an additional 272,136 shares during the period. Affinity Asset Advisors LLC boosted its stake in Nurix Therapeutics by 12.6% in the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock valued at $19,033,000 after acquiring an additional 101,747 shares during the period. Finally, Millennium Management LLC boosted its stake in Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after acquiring an additional 225,374 shares during the period.

Wall Street Analysts Forecast Growth

NRIX has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research report on Monday, October 21st. HC Wainwright raised their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Stephens restated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. Barclays raised their price objective on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, UBS Group initiated coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.